Search research articles
Contact Us
Filters
Showing results (1-10 of 1,957) with videos related to
Page
of 196
Sort By:
Current Neuropharmacology
|
June 2, 2010
Mmp-9, a potential target for cerebral ischemic treatment
Xue Dong, Yu-Ning Song, Wei-Guo Liu, et al.
Current Neuropharmacology
|
June 2, 2010
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I
R Miller
Current Neuropharmacology
|
June 2, 2010
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise
David M Marks, Manan J Shah, Ashwin A Patkar, et al.
Current Neuropharmacology
|
September 3, 2010
Past, present and future therapeutics for cerebellar ataxias
D Marmolino, M Manto
Current Neuropharmacology
|
September 3, 2010
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration
Anna L Bartels, Klaus L Leenders
Current Neuropharmacology
|
December 2, 2010
Aquaporins and glia
Roberta Albertini, Rossella Bianchi
Current Neuropharmacology
|
December 2, 2010
Aquaporin and vascular diseases
Carla Loreto, Ester Reggio
Current Neuropharmacology
|
December 2, 2010
Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update
Alberto Spalice, Pasquale Parisi, Laura Papetti, et al.
Current Neuropharmacology
|
December 2, 2010
Winning a won game: caffeine panacea for obesity syndemic
M Myslobodsky, A Eldan
Current Neuropharmacology
|
August 9, 2016
Erratum: Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
Page
of 196
Search research articles
Search
Showing results (1-10 of 1,957) with videos related to
Sort By:
Page
of 196
Current Neuropharmacology
|
June 2, 2010
Mmp-9, a potential target for cerebral ischemic treatment
Xue Dong, Yu-Ning Song, Wei-Guo Liu, et al.
Current Neuropharmacology
|
June 2, 2010
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I
R Miller
Current Neuropharmacology
|
June 2, 2010
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise
David M Marks, Manan J Shah, Ashwin A Patkar, et al.
Current Neuropharmacology
|
September 3, 2010
Past, present and future therapeutics for cerebellar ataxias
D Marmolino, M Manto
Current Neuropharmacology
|
September 3, 2010
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration
Anna L Bartels, Klaus L Leenders
Current Neuropharmacology
|
December 2, 2010
Aquaporins and glia
Roberta Albertini, Rossella Bianchi
Current Neuropharmacology
|
December 2, 2010
Aquaporin and vascular diseases
Carla Loreto, Ester Reggio
Current Neuropharmacology
|
December 2, 2010
Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update
Alberto Spalice, Pasquale Parisi, Laura Papetti, et al.
Current Neuropharmacology
|
December 2, 2010
Winning a won game: caffeine panacea for obesity syndemic
M Myslobodsky, A Eldan
Current Neuropharmacology
|
August 9, 2016
Erratum: Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
Page
of 196